Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Merger or Acquisition (October 2012)
25 slides from Biocryst Pharmaceuticals's merger presentation, Oct 18, 2012
Slide 1: BioCryst & Presidio Merger Overview
Exhibit 99.2 BioCryst & Presidio Merger Overview October 18, 2012
Slide 2: Disclaimer
Disclaimer Important Additional Information and Where to Find It BioCryst Pharmaceuticals, Inc. (“BioCryst”) intends to file with the SEC a registration statement on Form S-4, which will also include a proxy statement and prospectus with respect to the proposed acquisition of Presidio. The final pro
Slide 3: Two pronged focus: high-value antivirals & orphan indications
Two pronged focus: high-value antivirals & orphan indications HCV HAE Unique Revolutionary Experienced portfolio treatment Near-term leadership milestones Resourced to reach value creating events Three oral, pan-genotypic HCV molecules with distinct MOAs First oral prophylactic would revolutionize H
Slide 4: Transaction overview & capitalization plan
Transaction overview & capitalization plan • All Presidio assets • $25M cash committed from Presidio shareholders • 24.5M BCRX shares valued at $101M Minimum $60 million equity financing required as a closing condition Includes $25 million committed by Presidio shareholders Transaction & financing c
Slide 5: Hepatitis industry leaders joining an established leadership team
Hepatitis industry leaders joining an established leadership team NathanielBrown,MD, ChiefMedicalOfficer,Presidio - Former EVP Clinical Development & CMO, Idenix Pharmaceuticals; Head of Hepatitis Section, Infectious Disease, GlaxoWellcome/GSK - 23 years of experience in antiviral/antiinfective deve
Slide 6: Experienced governance & HCV investors: Board nominees
Experienced governance & HCV investors: Board nominees Presidio nominees to Board - Srinivas Akkaraju, MD, PhD Managing Director, New Leaf Venture Partners - FelixJ.Baker,PhD ManagingPartner,BakerBros.Advisors - KennethGalbraith GeneralPartner,VenturesWest Capital BioCryst nominees to Board - George
Slide 7: Hepatitis C Portfolio Overview
Hepatitis C Portfolio Overview
Slide 8: Opportunity for unique, all-oral, pan-genotypic combinations
Opportunity for unique, all-oral, pan-genotypic combinations HCV Mechanism of Action Preclinical Phase 1 Status NS5A inhibitor PPI-668 Ph 2 ready Nucleoside NS5B inhibitor BCX5191 Ph 1 ready 4Q12 Non-nucleoside NS5B inhibitor PPI-383 Ph 1 ready 1H13 PPI-668 PPI-668 PPI-668 + + + BCX5191 BCX5191 PPI-
Slide 9: NS5A inhibitor: Potential foundation for curative combinations
NS5A inhibitor: Potential foundation for curative combinations Aggressively pursue external collaborations to identify optimal regimens Internal/external Internal combinations combinations Additional DAAs from BCX5191 external PPI-668 + and/or sources PPI-383 Opportunity to address significant HCV m
Slide 10: PPI-668 is an "optimized" NS5A inhibitor
PPI-668 is an “optimized” NS5A inhibitor PPI-668 BMS-052 Oral, QD dosing in humans 10 Pan-genotypic coverage of all major HCV genotypes – Equivalent to daclatasvir (BMS-052) Additive to synergistic with other 1 classes of HCV antivirals, no antagonism noted Excellent safety profile in 3-month animal
Slide 11: Favorable PPI-668 pharmacokinetic (PK) profile
Favorable PPI-668 pharmacokinetic (PK) profile Phase – 1a results Completed single & multi-dose 6000 administration (40-320 mg once daily) 80 mg 160 mg All doses generally safe & well 320 mg 5000 tolerated Micromolar blood levels within 2 hr, for rapid HCV inhibition PK results support once-daily do
Slide 12: PPI-668: Optimal PK profile with once-daily dosing
PPI-668: Optimal PK profile with once-daily dosing 10000 Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 5-day once-daily oral dosing @ 320 mg Intensive PK sampling after 1st & 5th doses; 1000 trough levels (C 24hr) on other days Steadystateachievedby Day 2, no subsequent accumulation or 100 induced elimination
Slide 13: PPI-668 Phase 1b: POC & antiviral activity demonstrated
PPI-668 Phase 1b: POC & antiviral activity demonstrated Phase 1b design 10 patients per dose cohort, randomized 8:2 (active : placebo) 40, 80, 160 or 240 mg QD x 3 days, with 14 days follow up 3-day dosing consistent with draft FDA HCV guidance Results Well tolerated at all doses Mean maximal HCV RN
Slide 14: Two complementary inhibitors of HCV NS5B polymerase
Two complementary inhibitors of HCV NS5B polymerase NS5B protein serves as the viral polymerase & is essential for HCV replication Allosteric Adenosine non-nucleoside nucleoside inhibitor inhibitor PPI-383 BCX5191 • Opportunity to • Opportunity to develop a superior develop highly NNuc as a 3rd clas
Slide 15: PPI-383 (NNuc) exhibits pan-genotypic activity in replicon assays
PPI-383 (NNuc) exhibits pan-genotypic activity in replicon assays NNucs currently in advanced 10000 development are HCV GT-1 specific PPI-383 PPI-383 distinct feature: near VX-222 equivalent coverage of HCV 1000 genotypes tested Additive to synergistic with other 100 classes of HCV antivirals Favora
Slide 16: BCX5191 (Nuc): Pan-genotypic at sub-micromolar concentrations
BCX5191 (Nuc): Pan-genotypic at sub-micromolar concentrations Adenosine nucleoside analog BCX5191 * GS-7977 Pan-genotypic coverage 10000 Sub-micromolar potency on NS5B Compares favorably with GS-7977 1000 Favorable pharmacological profile: Metabolic stability No CYP inhibition 100 Parent drug plasma
Slide 17: Hereditary Angioedema Overview
Hereditary Angioedema Overview
Slide 18: BCX4161 could be the first oral prophylactic HAE therapy
BCX4161 could be the first oral prophylactic HAE therapy Problems with current parenteral KK inhibitors: IV infusions create a significant treatment burden IV access maintenance Risk of infection SC injection reactions Goals of BCX4161 development program: Oral administration Highly effective attack
Slide 19: BCX4161 targets kallikrein, which is fully validated clinically in HAE
BCX4161 targets kallikrein, which is fully validated clinically in HAE 1 Trauma Inhibit kallikrein activity Prekallikrein Cinryze —IV prophylaxis Factor XIIa Berinert —IV acute therapy Plasmin 1 Kalbitor —SC acute therapy Kallikrein BCX4161 —Oral prophylaxis High-Molecular-Weight 2 Bradykinin Kinino
Slide 20: BCX4161 has demonstrated preclinical POC for oral dosing
BCX4161 has demonstrated preclinical POC for oral dosing Inhibition of kallikrein activity through 24 hours post-dose PK of BCX4161 in rats – Pharmacodynamics of BCX4161 in rats – 30, 100 & 300 mg/kg oral dosing 100 mg/kg oral dosing 100000 100 30 mg/kg 100 100 mg/kg 80 10000 300 mg/kg 50% 10 Kl 60
Slide 21: BCX4161 inhibits Kallikrein at very low doses
BCX4161 inhibits Kallikrein at very low doses Inhibition of kallikrein in plasma from 51 BCX4161 inhibits kallikrein normal subjects: 50 EC< 12 nM in all cases in human plasma Median EC 50 ~ 6 nM BCX4161 at 50-100 nM maximally inhibits kallikrein Phase 1 trial will deliver: Preliminary safety PK fro
Slide 22: BCX4161 profile for HAE: Entering Phase 1 4Q12
BCX4161 profile for HAE: Entering Phase 1 4Q12 Profile Results BCX4161 inhibits kallikrein in human plasma Attractive preclinical pharmacology Median EC50 ~ 6 nM profile Preclinical POC for oral dosing IND-enabling program complete Nonclinical safety Therapeutic window assessed Doses selected for fi
Slide 23: Pipeline with development focus on HCV & HAE
Pipeline with development focus on HCV & HAE Disease Program Pre-IND Phase 1 Phase 2 Pivotal Approved PPI-668 HCV NS5A inhibitor BCX5191 Nucleoside NS5B PPI-383 Non-nucleoside NS5B BCX4161 HAE Oral kallikrein inhibitor Peramivir, i.v. 1 Other Outpatient, seasonal influenza Peramivir, i.v. Inpatient,
Slide 24: Important near-term events support value creation
Important near-term events support value creation 2012 2013 4Q 1Q 2Q 3Q 4Q Complete merger AASLD AASLD EASL BCX5191 Phase 1 results PPI-668 Phase 2a combo results PPI-383 Phase 1 results BCX4161 Phase 1 results Peramivir Phase 3 interim analysis HCV events HAE events Business events Influenza events
Slide 25: A well-capitalized HCV player with numerous value creating events
A well-capitalized HCV player with numerous value creating events Attractive assets HCV HAE Unique Revolutionary portfolio treatment Experienced Near-term leadership Shareholder value milestones Resourced to reach value creating events NewCo 25
BioCryst Pharmaceuticals — Merger or Acquisition (October 2012) on 6ix